Carmell Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Carmell Therapeutics
CTCX Stock   0.43  0.01  3.33%   
Carmell Therapeutics financial statements provide useful quarterly and yearly information to potential Carmell Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Carmell Therapeutics financial statements helps investors assess Carmell Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Carmell Therapeutics' valuation are summarized below:
Gross Profit
12 K
Market Capitalization
12.9 M
Enterprise Value Revenue
381.2726
Revenue
12.3 K
Earnings Share
0.48
We have found one hundred sixteen available fundamental signals for Carmell Therapeutics, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Carmell Therapeutics prevailing market performance against the performance between 2010 and 2025 to make sure the company can sustain itself down the road. Market Cap is likely to drop to about 45.9 M in 2025. Enterprise Value is likely to drop to about 45 M in 2025
Check Carmell Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Carmell Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Depreciation And Amortization of 162.5 K or Interest Expense of 760.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.6. Carmell financial statements analysis is a perfect complement when working with Carmell Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Carmell Therapeutics Correlation against competitors.
For more information on how to buy Carmell Stock please use our How to Invest in Carmell Therapeutics guide.

Carmell Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets77.2 M73.5 M14.7 M
Slightly volatile
Short and Long Term Debt Total1.8 M1.9 M7.9 M
Slightly volatile
Other Current Liabilities39.4 M37.5 M11.6 M
Slightly volatile
Total Current Liabilities22.6 M44.3 M18.9 M
Slightly volatile
Property Plant And Equipment Net929.1 K922.1 K1.3 M
Slightly volatile
Current Deferred Revenue2.4 M3.2 M2.4 M
Pretty Stable
Accounts Payable2.7 M5.1 M1.6 M
Slightly volatile
Cash3.5 M3.3 M628.4 K
Slightly volatile
Non Current Assets Total952 K943.8 K1.3 M
Slightly volatile
Long Term Debt738830905
Slightly volatile
Cash And Short Term Investments3.5 M3.3 M628.4 K
Slightly volatile
Common Stock Shares Outstanding13.5 M9.9 M18.2 M
Slightly volatile
Liabilities And Stockholders Equity77.2 M73.5 M14.7 M
Slightly volatile
Non Current Liabilities Total596.5 K627.9 K13.6 M
Slightly volatile
Capital Lease Obligations769.9 K763.1 K1 M
Slightly volatile
Other Current Assets72.2 M68.8 M12.7 M
Slightly volatile
Other Stockholder Equity100.5 M95.7 M20.1 M
Slightly volatile
Total Liabilities40.3 M45.1 M33.6 M
Slightly volatile
Property Plant And Equipment Gross1.4 M1.5 M1.7 M
Slightly volatile
Short and Long Term Debt1.1 M1.2 M6.8 M
Slightly volatile
Total Current Assets76 M72.3 M13.4 M
Slightly volatile
Capital Stock2 K2.1 K29 K
Slightly volatile
Short Term Debt1.2 M1.3 M7 M
Slightly volatile
Intangible Assets23 K21.8 K31 K
Slightly volatile
Common Stock2 K2.1 K29 K
Slightly volatile
Net Receivables163.6 K184.1 K200.7 K
Slightly volatile

Carmell Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization162.5 K112.3 K221.7 K
Slightly volatile
Interest Expense760.4 K800.4 K2.3 M
Slightly volatile
Selling General Administrative2.5 M3 M1.4 M
Slightly volatile
Other Operating Expenses4.6 M6 M2.8 M
Slightly volatile
Research Development2.1 M2.9 M1.3 M
Slightly volatile
Total Operating Expenses4.6 M5.9 M2.8 M
Slightly volatile
Reconciled Depreciation162.5 K112.3 K221.7 K
Slightly volatile
Cost Of Revenue146.9 K112.3 K221.1 K
Slightly volatile

Carmell Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Change In Cash3.4 M3.2 M599.9 K
Slightly volatile
Stock Based Compensation568.6 K767.8 K350.1 K
Slightly volatile
Begin Period Cash Flow154.7 K147.4 K28.5 K
Slightly volatile
Other Cashflows From Financing Activities17.3 M16.5 M3.1 M
Slightly volatile
Depreciation162.5 K112.3 K221.7 K
Slightly volatile
Other Non Cash Items11.7 M11.2 M3.2 M
Slightly volatile
Capital Expenditures36.8 K35 K12.3 K
Slightly volatile
Total Cash From Financing Activities13.5 M12.8 M3.5 M
Slightly volatile
End Period Cash Flow3.5 M3.3 M628.4 K
Slightly volatile
Other Cashflows From Investing Activities123.6 M139 M151.5 M
Slightly volatile
Change To Inventory163.6 K184.1 K200.7 K
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Average Payables1.2 M1.4 M1.5 M
Slightly volatile
Capex To Depreciation0.230.220.0678
Slightly volatile
Payables Turnover0.03090.03250.0979
Slightly volatile
Cash Per Share0.250.240.048
Slightly volatile
Days Payables Outstanding6.5 K11.6 K4.6 K
Slightly volatile
Income Quality0.30.490.2431
Slightly volatile
Intangibles To Total Assets4.0E-44.0E-40.0171
Slightly volatile
Current Ratio1.541.470.3039
Slightly volatile
Graham Number4.317.574.0369
Slightly volatile
Capex Per Share0.00260.00258.0E-4
Slightly volatile
Average Receivables81.8 K92.1 K100.4 K
Slightly volatile
Interest Debt Per Share0.460.320.5519
Slightly volatile
Debt To Assets0.03650.03844.8059
Slightly volatile
Days Of Payables Outstanding6.5 K11.6 K4.6 K
Slightly volatile
Ebt Per Ebit2.973.573.2099
Slightly volatile
Quick Ratio1.541.470.3039
Slightly volatile
Net Income Per E B T0.760.860.9352
Slightly volatile
Cash Ratio0.07150.06810.0151
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.11.151.0206
Slightly volatile
Debt Ratio0.03650.03844.8059
Slightly volatile

Carmell Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap45.9 M48.3 M163.4 M
Slightly volatile
Enterprise Value45 M47.4 M170.7 M
Slightly volatile

Carmell Fundamental Market Drivers

Cash And Short Term Investments2.9 M

Carmell Upcoming Events

13th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Carmell Therapeutics Financial Statements

Carmell Therapeutics investors use historical fundamental indicators, such as Carmell Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Carmell Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue3.2 M2.4 M
Cost Of Revenue112.3 K146.9 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
EBRCentrais Electricas Brasileiras
HEHawaiian Electric Industries
VFCVF Corporation

Additional Tools for Carmell Stock Analysis

When running Carmell Therapeutics' price analysis, check to measure Carmell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Carmell Therapeutics is operating at the current time. Most of Carmell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Carmell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Carmell Therapeutics' price. Additionally, you may evaluate how the addition of Carmell Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY